FDA/CDC

Two PR employees at FDA fired after plasma therapy controversy


 

The US Food and Drug Administration has removed two senior public relations employees, one of whom advised the agency against unbridled promotion of convalescent blood plasma as a treatment for people with COVID-19, multiple media outlets reported Aug. 28.

Officials claim the dismissals are coincidental and are not related to a controversy about whether claims regarding convalescent plasma therapy that were put forth by President Donald Trump and FDA Commissioner Stephen M. Hahn, MD, were exaggerated, according to reports from The New York Times , CNN, and elsewhere.

One of the PR employees, Emily Miller, was on the job less than 2 weeks. The White House named her FDA chief spokeswoman 11 days ago, but Hahn removed her from that post Aug. 28.

On Aug. 27, the US Department of Health and Human Services terminated the contract for Wayne L. Pines, a PR consultant to the FDA. Pines reportedly advised Hahn to apologize for making misleading claims about the therapeutic benefits of convalescent plasma therapy for COVID-19.

The FDA did not respond to multiple requests for comment.

The controversy stems from comments Hahn made about the announcement of the emergency use authorization for convalescent plasma for patients with COVID-19. He said that plasma had been found to save the lives of 35 out of every 100 people who were treated. That statement was later found to be erroneous because he presented a relative risk reduction as an absolute decrease in risk. He later apologized via Twitter.

Researchers running clinical trials to evaluate the efficacy of convalescent plasma for COVID-19 are concerned that the emergency use authorization could thwart efforts to recruit participants for their studies.

This article first appeared on Medscape.com.

Recommended Reading

First evidence of SARS-CoV-2 in heart cells
MDedge Hematology and Oncology
When viruses collide: Flu season during pandemic
MDedge Hematology and Oncology
Prognosis for rural hospitals worsens with pandemic
MDedge Hematology and Oncology
Convalescent plasma actions spark trial recruitment concerns
MDedge Hematology and Oncology
Asymptomatic SARS-CoV-2 infections in kids tied to local rates
MDedge Hematology and Oncology
COVID-19 vaccine supply will be limited at first, ACIP says
MDedge Hematology and Oncology
FDA approves point-of-care COVID-19 antigen test
MDedge Hematology and Oncology
Mitigating psychiatric disorder relapse in pregnancy during pandemic
MDedge Hematology and Oncology
SARS-CoV-2 appears unlikely to pass through breast milk
MDedge Hematology and Oncology
NYC public hospitals rose to the demands of the COVID-19 crisis
MDedge Hematology and Oncology